Chronic liver fibrosis mitigated by mouse hepatocytes
The new study provides proof of principle that functional liver cells can be grown in a different species, offering a potential solution to transplant shortage.
List view / Grid view
The new study provides proof of principle that functional liver cells can be grown in a different species, offering a potential solution to transplant shortage.
The discovery that omental fat has a mechanism to limit adipocyte formation may lead to new treatments for obesity and metabolic disease.
In this Q&A, Simon Kerry, CEO of Curve Therapeutics, shares the company’s recent milestones, insights into the innovative Microcycle platform, and how Curve plans to remain on the cutting edge of drug discovery.
Researchers have revealed that genetically enhanced expression of GSDMB causes a disturbed interferon-response.
Injections of cardiac spheroids into primate ventricles improved left ventricular ejection after four weeks.
The pharmacological inhibition of class IIa HDACs could be a therapeutic approach for addressing Th17-related inflammatory and autoimmune diseases.
The new findings could lead to new therapeutics and a method to diagnose pancreatic cancer earlier, improving its prognosis.
The discovery that genomic deletions cause altBRAFs can help develop new therapies to overcome drug resistance in BRAF-mutant melanoma.
In this Q&A, Associate Professor Dr Mete Civelek shares insights from the University of Virginia’s exciting recent study identifying several potential therapeutic targets for accelerating translational research in cardiovascular disease treatment, with a focus on proteins associated with the extracellular matrix (ECM) secretion by smooth muscle cells (SMCs).
In this Q&A, Curve Therapeutic’s Chief Scientific Officer Professor Ali Tavassoli discusses how dual HIF inhibition could combat solid tumours.
IFNβ could be developed into a new therapy, following an improved understanding of how innate immunity affects the brain during chronic HIV infection.
In this Q&A, Dr Nicholas Waters, Head of R&D at IRLAB, shares how three compounds, including IRLABs Mesdopetam and an experimental dopamine D3 receptor antagonist, could reverse features associated with the psychosis-like state of Parkinson’s disease.
Researchers find how antibiotic treatments influence the microbiota, providing new strategies for preventing antibiotic-induced damage.
The discovery that one missing copy of MUTYH could increase the risk of cancers may lead to therapeutics against solid tumours.
Mutation in two copies of the IKBKB gene leads to abnormal function of regulatory T cells, causing psoriatic arthritis.